U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07939529) titled 'People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness' on Nov. 10.
Brief Summary: This pilot, single-arm, open-label study conducted in the United States will evaluate the efficacy, safety, tolerability, and pharmacokinetics of long-acting lenacapavir plus cabotegravir (LA LEN+CAB) in people with HIV-1 viremia who have a history of non-adherence and confirmed or suspected rilpivirine (RPV) resistance. Participants will be on study for up to 108 weeks.
Study Start Date: Feb. 01, 2028
Study Type: INTERVENTIONAL
Condition:
HIV Viremia
Intervention:
DRUG: Lenacapavir
Long-acting subcut...